Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Petosemtamab + Chemotherapy vs Cetuximab/Bevacizumab + Chemotherapy in 2L Colorectal Cancer
NCT07775287Phase 3Recruiting
- Sponsor
- Genmab
- Start
- Oct 2026
- Primary completion
- Mar 2029
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of petosemtamab in colorectal cancer (CRC) (2 arms), sponsored by Genmab. Primary endpoints: Progression-free Survival and Objective Response Rate. Started Oct 2026; status: recruiting.
02
Drugs
petosemtamab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07775287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07775287.